ArticleAmerican journal of cancer research2017
LncRNA HOXD-AS1 promotes melanoma cell proliferation and invasion by suppressing RUNX3 expression.
Article in American journal of cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 50 citations in OpenAlex.
- Non-coding RNAs in programmed cell death regulation in melanoma: mechanisms and therapeutic insights.Discover oncology · 2025Review
- A symphony of signals: the intricate role of lncRNAs in dermatological disorders.Clinical and experimental medicine · 2025Review
- Long noncoding HOXD-AS1: a crucial regulator of malignancy.Frontiers in cell and developmental biology · 2025Review
- LncRNA SLNCR1 facilitates angiogenesis and tumor growth in melanoma via DNMT1-mediated epigenetically silencing SPRY2.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- A novel long non-coding RNA SLNCR1 promotes proliferation, migration, and invasion of melanoma via transcriptionally regulating SOX5.Cell death discovery · 2024Article
- Lnc-PKNOX1-1 inhibits tumor progression in cutaneous malignant melanoma by regulating NF-κB/IL-8 axis.Carcinogenesis · 2023Article
- LncRNA HAGLR May Aggravate Melanoma Malignancy Via miR-4644/ASB11 Pathway.Molecular biotechnology · 2023Article
- Pathogenic roles of long noncoding RNAs in melanoma: Implications in diagnosis and therapies.Genes & diseases · 2023Review
- lncRNAs-EZH2 interaction as promising therapeutic target in cutaneous melanoma.Frontiers in molecular biosciences · 2023Review
- BBOX1-AS1 contributes to colorectal cancer progression by sponging hsa-miR-361-3p and targeting SH2B1.FEBS open bio · 2022Article
- Identification of Immune-Related Prognostic mRNA and lncRNA in Patients with Hepatocellular Carcinoma.Journal of oncology · 2022Article
- WZY-321 triggers glioma cell apoptosis via XAF1 up-regulation caused by MTM-mediated miR-873 down-regulation.Journal of Cancer · 2022Article
- Regulation of RUNX proteins by long non-coding RNAs and circular RNAs in different cancers.Non-coding RNA research · 2021Review
- LINC00470 accelerates the proliferation and metastasis of melanoma through promoting APEX1 expression.Cell death & disease · 2021Article
- Downregulation of lncRNA TSLNC8 promotes melanoma resistance to BRAF inhibitor PLX4720 through binding with PP1α to re-activate MAPK signaling.Journal of cancer research and clinical oncology · 2021Article
- Long non-coding RNA MCM3AP-AS1 facilitates colorectal cancer progression by regulating the microRNA-599/ARPP19 axis.Oncology letters · 2021Article
- Article
- LncRNA HOXD-AS1 promotes the metastasis of human hepatocellular carcinoma via modulating miR-326/SLC27A4.Cancer cell international · 2020Article
- HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2.Open biology · 2019Article
- Long noncoding RNA LINC00520 prevents the progression of cutaneous squamous cell carcinoma through the inactivation of the PI3K/Akt signaling pathway by downregulating EGFR.Chinese medical journal · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long non-coding RNAs (lncRNAs) act as critical regulators of many malignant tumors cellular processes including cell proliferation, differentiation, apoptosis, invasion and metastasis. However, the functions and molecular mechanisms of lncRNA HOXD-AS1 in melanoma remain little known. In the present study, we observed that lncRNA HOXD-AS1 expression was remarkably higher in melanoma tissues compared to skin tissues with melanocytic nevus. Increased expression of lncRNA HOXD-AS1 correlated with poor survival of melanoma patients. Furthermore, functional experiments demonstrated that upregulated lncRNA HOXD-AS1 expression dramatically promoted cell proliferation and invasion of melanoma, while downregulation of lncRNA HOXD-AS1 showed a tumor inhibiting effects on melanoma cells in vitro. In vivo, data results showed that lncRNA HOXD-AS1 knockdown notably reduced tumor growth. Additionally, RNA immunoprecipitation (RIP) and Chromatin immunoprecipitation (ChIP) assays revealed that lncRNA HOXD-AS1 could epigenetically suppress the expression of RUNX3 via binding to EZH2. Downregulation of RUNX3 attenuated the proliferation and invasion-inhibiting effects induced by lncRNA HOXD-AS1 knockdown in melanoma cells. Therefore, these results indicated that HOXD-AS1 may serve as a potential therapeutic target of melanoma.
Indexed as
Identifiers
29312805PMC5752692W2946977268What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.